MiRNA therapy for Myocardial dysfunction: MiR-765 increases CDK inhibitor p27 expression, inhibits mTOR pathway, promotes autophagy in myocardial cells and prevents myocardial dysfunction via down-regulation of its target gene, 22/October/2016, 6.51 am

Natural product therapy for tuberculosis: Fructus Ligustri Lucide extract increases the expression of MKP-1, inhibits TLR2 signalling, secretion of Chemokine CXCL5, and recruitment of polymorphonuclear leukocytes (PMNs), decreases destructive pulmonary inflammation , promotes M. tuberculosis clearance and inhibits pulmonary tuberculosis via up-regulation of its target gene, 21/October/2016, 5.03 pm
October 21, 2016
Natural product Anti-telomerase cancer therapy: Moringa oleifera (MO) extract suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of its target gene, 22/October/2016, 7.05 am
October 22, 2016
Show all

Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports here that: MiRNA therapy for Myocardial dysfunction: MiR-765 increases CDK inhibitor p27 expression, inhibits mTOR pathway, promotes autophagy in myocardial cells and prevents myocardial dysfunction via down-regulation of its target gene



Significance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find: (i)  a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free drug.


Research Findings: 

MiR-765 , by decreasing the expression of its target gene,  it may: (1) increase the expression of marker of autophagy LC3-II, 2) inhibit selective autophagy receptor p62/sequestosome 1 (SQSTM1) expression,  3) inhibit the expression of negative regulator of autophagy, mTOR, 4) promote autophagy, 5) increase CDK inhibitor p27 expression, 6) decrease left ventricular end-diastolic internal diameter and heart size, and (5) inhibit cardiomyocyte dysfunction. Together, this study suggests that pharmacological formulations encompassing ” MiR-765 or its activators” may be used to improve cardiac function.


Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, MiRNA therapy for Myocardial dysfunction: MiR-765 increases CDK inhibitor p27 expression, inhibits mTOR pathway, promotes autophagy in myocardial cells and prevents myocardial dysfunction via down-regulation of its target gene, 22/October/2016, 6.51 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

# Research cooperation


Amount: $200#

Undisclosed information: How MiR-765 promotes autophagy in cardiomyocytes and prevents heart failure.

satisfaction-guaranted-if-not-refunded

Results guaranteed if not refunded

Comments are closed.